- Home
- VYGR vs KG Comparison
VYGR vs KG Comparison
Compare VYGR & KG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- KG
- Stock Information
- Founded
- VYGR 2013
- KG N/A
- Country
- VYGR United States
- KG Bermuda
- Employees
- VYGR N/A
- KG N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- KG Property-Casualty Insurers
- Sector
- VYGR Health Care
- KG Finance
- Exchange
- VYGR Nasdaq
- KG Nasdaq
- Market Cap
- VYGR 231.9M
- KG 225.0M
- IPO Year
- VYGR 2015
- KG N/A
- Fundamental
- Price
- VYGR $4.69
- KG $25.73
- Analyst Decision
- VYGR Strong Buy
- KG
- Analyst Count
- VYGR 8
- KG 0
- Target Price
- VYGR $16.71
- KG N/A
- AVG Volume (30 Days)
- VYGR 789.3K
- KG 43.5K
- Earning Date
- VYGR 11-11-2025
- KG 11-15-2025
- Dividend Yield
- VYGR N/A
- KG N/A
- EPS Growth
- VYGR N/A
- KG N/A
- EPS
- VYGR N/A
- KG 9.13
- Revenue
- VYGR $42,580,000.00
- KG $9,983,137.00
- Revenue This Year
- VYGR N/A
- KG N/A
- Revenue Next Year
- VYGR $107.10
- KG N/A
- P/E Ratio
- VYGR N/A
- KG $2.84
- Revenue Growth
- VYGR N/A
- KG 250.18
- 52 Week Low
- VYGR $2.65
- KG $20.51
- 52 Week High
- VYGR $8.28
- KG $36.80
- Technical
- Relative Strength Index (RSI)
- VYGR 62.56
- KG 40.61
- Support Level
- VYGR $4.32
- KG $25.47
- Resistance Level
- VYGR $5.06
- KG $26.58
- Average True Range (ATR)
- VYGR 0.29
- KG 0.92
- MACD
- VYGR 0.02
- KG -0.23
- Stochastic Oscillator
- VYGR 64.59
- KG 7.10
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About KG Kestrel Group Ltd.
Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.